Regeneron Pharmaceuticals, Inc. has been the focus of several asset management strategies, with numerous establishments buying, selling, and modifying their stakes in REGN. High confidence exists in the approval of the company's promising drug,
Odronextamab. In addition, price targets are being adjusted by several bodies, such as BMO Capital, Sanford C. Bernstein, and Jefferies Financial Group. The
FDA has approved
Linvoseltamab for multiple myeloma and extended review deadlines for two additional Regeneron submissions. Potential game-changers involve
Cemdisiran's Phase 3 success and studies on
Pozelimab and Cemdisiran in PNH treatment,
REGN7508 in thromboprophylaxis, and
Regeneron’s REGN7544 for sepsis-induced hypotension, as well as a collaboration with
Sanofi on an immunology project. Analysts have given REGN a moderate buy rating with many anticipating its stocks to rebound due to strong sales, potential product launches, and innovative R&D progress.
Regeneron Pharmaceuticals REGN News Analytics from Fri, 09 May 2025 07:00:00 GMT to Sat, 30 Aug 2025 21:40:35 GMT -
Rating 5
- Innovation 7
- Information 9
- Rumor 4
